Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure
Status:
Completed
Trial end date:
2017-08-15
Target enrollment:
Participant gender:
Summary
This study investigates the presence of a possible link between treatment with danazol and
expression of endometrial αvβ3 integrin which might allow tailoring of danazol treatment to
the subset of repeated IVF/ET failure that might benefit most from it.
38 eligible ovulatory women were recruited aged 20 - 38 years with unexplained recurrent
implantation failure (RIF). Timed suction endometrial biopsy was obtained from participants
during the implantation window of the pretreatment cycle, followed by immunohistochemical
staining for endometrial αvβ3 integrin expression, scored using H-score.
Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in
daily dosage of 400 mg for 12 weeks. Post-treatment suction endometrial biopsy was obtained
during the implantation window following the first ovulation after danazol treatment and
endometrial αvβ3 integrin expression was compared to the pretreatment cycle.